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Abstract
Diabetes and depression occur together approximately twice as frequently as would be predicted 
by chance alone. Comorbid diabetes and depression are a major clinical challenge as the outcomes 
of both conditions are worsened by the other. Although the psychological burden of diabetes may 
contribute to depression, this explanation does not fully explain the relationship between these 2 
conditions. Both conditions may be driven by shared underlying biological and behavioral 
mechanisms, such as hypothalamic-pituitary-adrenal axis activation, inflammation, sleep 
disturbance, inactive lifestyle, poor dietary habits, and environmental and cultural risk factors. 
Depression is frequently missed in people with diabetes despite effective screening tools being 
available. Both psychological interventions and antidepressants are effective in treating depressive 
symptoms in people with diabetes but have mixed effects on glycemic control. Clear care 
pathways involving a multidisciplinary team are needed to obtain optimal medical and psychiatric 
outcomes for people with comorbid diabetes and depression.
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Introduction
With diabetes and mental illness affecting approximately 8.3 % and 10 % of the total 
world’s population, respectively [1, 2], a degree of comorbidity between diabetes and 
depression is to be expected. However, epidemiologic studies have shown consistently that 
the 2 conditions occur together approximately twice as frequently as would be predicted by 
chance alone [3]. The combination of diabetes and depression present a major clinical 
challenge as the outcomes of both conditions are worsened by the presence of the other. 
Quality of life is worse, diabetes self-management is impaired, the incidence of 
complications is increased and life expectancy is reduced [4]. The costs of treatment 
increase significantly for both individual patients and health economies but these costs do 
not necessarily result in significant improvements in disease or quality of life outcomes [5].
The association between mental illness and diabetes has been recognized for many years [6]. 
In the 17th century, Thomas Willis, the famous anatomist and founding member of the 
Royal Society, described how “diabetes is a consequence of prolonged sorrow” [7]. 
Nevertheless, it is a frequently ignored yet vital component of holistic diabetes care. This 
review will explore the association between the 2 conditions, highlighting the epidemiology, 
pathogenesis and treatment options.
Methods
The authors prepared this review from literature searches in PubMed and data presented at 
the International Diabetes and Depression Conference held in Washington, DC in October 
2012, which was hosted by the National Institute of Diabetes, Digestive, and Kidney 
Diseases (NIDDK) of the National Institutes of Health (NIH) in collaboration with the 
National Institute of Mental Health and the Dialogue on Diabetes and Depression [8, 9].
Epidemiology of Diabetes and Depression
Significant depressive symptoms affect approximately 1 in 4 adults with type 1 and type 2 
diabetes, whereas a formal diagnosis of depressive disorders is made in approximately 10 
%–15 % of people with diabetes [3]. The prevalence estimates vary widely because of 
methodological differences in the definition of depression. In some studies, the term 
‘depression’ means self-reported high depressive symptom scores, whereas in others it 
reflects a formal diagnosis by psychiatric interview. In addition, the construct of ‘diabetes-
related distress’ captures the emotional distress associated with diabetes self-management, 
social support, and health care [10]. This construct has been found to be modestly correlated 
with depressive symptoms with approximately 30 % overlapping variance but remains 
distinct from depression in its association with adherence and glycemic control [10, 11].
A recent meta-analysis of 11 studies including nearly 50,000 people with type 2 diabetes but 
without depression at baseline has indicated that the incidence of depression is also 24 % 
higher in people with diabetes [12]. Once depressive symptoms occur or a diagnosis of 
depression is made, the symptoms appear to be persistent. For example, Peyrot and Rubin 
found self-reported depressive symptoms persisted in 73 % of people 12 months after a 
diabetes education program [13]. Furthermore, Lustman and colleagues observed a relapse 
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rate for diagnosed major depressive disorder of 79 % over a 5-year period [14]. These data 
are in contrast to general population studies that suggest a depressive episode usually lasts 
8–12 weeks indicating that in people with diabetes depressive episodes are more long-
lasting and more likely recurrent.
There have been few studies of depression in children and adolescents but these suggest that 
rates of depression are also elevated in either type 1 or type 2 diabetes with prevalence rates 
ranging from 9 %–26 % [15].
As observed by Thomas Willis, epidemiologic studies have demonstrated that the 
association between depression and diabetes is bi-directional [16, 17]. A meta-analysis of 9 
cohort studies found that adults with depression had a 37 % increased risk of developing 
type 2 diabetes [18] after accounting for factors common to both disorders including sex, 
body mass index, and poverty. There was considerable heterogeneity across studies with the 
risk varying between a nonsignificant increased relative risk of 1.03 to 2.50. A further meta-
analysis of 13 studies found incident depression was increased by 15 % (OR 1.15 (95 % CI 
1.02–1.30)) in people with diabetes at baseline [16].
General population risk factors for depression, including female sex, marital status, 
childhood adversity, and social deprivation also apply to people with diabetes. In addition, 
there are a number of diabetes specific risk factors associated with depression. In people 
with type 2 diabetes, the rates of depression are higher amongst those using insulin 
compared with noninsulin medications or dietary and lifestyle interventions alone [19, 20]. 
This does not imply that the insulin itself is causative but may reflect disease progression 
and the increased treatment demands made on an individual when insulin is initiated. The 
development of diabetes complications, particularly sexual dysfunction and painful 
peripheral neuropathy, also predict the development of depression [21]. In a specialized 
outpatient clinic, the presence of 2 or more complications was associated with a greater than 
2-fold increase in the risk of depression in people with type 2 diabetes, with neuropathy and 
nephropathy showing the strongest association with depression [22]. Other diabetes specific 
risk factors include recurrent hypoglycemia and poor glycemic control. Two trials have 
reported that intensive self-monitoring of blood glucose has an adverse effect on depression 
rates in people with type 2 diabetes although other studies found no effect [20].
The Mechanisms and Pathogenesis Underlying the Association Between 
Diabetes and Depression
A variety of explanatory theoretical models have been proposed to explain the comorbidity 
of diabetes and depression.
Clinical Burden of Disease
Traditionally it was widely believed that depression was an understandable reaction to the 
difficulties resulting from living with a demanding and life-shortening chronic physical 
illness that is associated with debilitating complications. This model is supported by a 
systematic review of 11 studies that found no difference in the rates of depression between 
those with undiagnosed diabetes, those with impaired glucose metabolism, and people with 
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normal glucose metabolism [23••]. An increased rate of depression was only found in those 
with diagnosed diabetes suggesting that the knowledge of the diagnosis and the burden of 
managing the condition and its complications are associated with depressive symptoms 
rather than biological mechanisms such as hyperglycemia. The implication of this finding is 
that healthcare professionals may have an important role in moderating the psychological 
burden associated with diabetes by considering the way in which the diagnosis of diabetes is 
conveyed and the psychosocial support that is given at and after diagnosis.
Lifestyle Factors and Adherence
Lifestyle factors are hypothesized to play a role in priming or reinforcing the comorbidity of 
depression and diabetes. For example, people with depression are more likely to be 
sedentary and eat diets that are rich in saturated fats and refined sugars while avoiding fruit 
and vegetables, which may contribute to the increased risk of developing type 2 diabetes 
[24–26].
Nonadherence to self-care management in those already diagnosed with diabetes and 
experiencing depressive symptoms has also been found [27, 28]. A meta-analysis of 47 
independent samples found that depression was significantly associated with nonadherence 
to diabetes treatment recommendations including missed medical appointments, diet, 
exercise, medication use, glucose monitoring, and foot care [27]. In a primary care study of 
879 people with type 2 diabetes, a 1-point increase in depressive symptoms scores was 
found to result in a 10 % increased risk of nonadherence to fruit and vegetable intake and 
foot care [28]. This suggests the possibility that there may be a mutually-reinforcing 
phenomenon that poorer adherence to self-care may increase blood glucose, which in turn 
may contribute to depressive symptoms and consequently contribute to decreased adherence 
to self-care behaviors.
Antidepressant Medications
It is also possible that the use of antidepressants contributes to the risk of diabetes. Case 
reports, and observational studies have shown a consistent association between people 
receiving antidepressant medications and diabetes but whether this relationship is causative 
remains unproved [29•]. Randomized controlled trials have emphasized that antidepressants 
vary considerably in their association with weight gain and both hyperglycemic and 
hypoglycemic effects have been observed [29•].
Brain Structure and Function
In addition to the psychosocial models described above, there are a number of shared 
biological changes that occur in diabetes and depression that may increase the risk of the 
other condition (Fig. 1). These mechanisms provide a novel perspective in considering the 
association between depression and diabetes by focusing more on common pathogenic 
mechanisms rather than focusing on the direction of association.
It is well recognized that both hypoglycemia and hyperglycemia can have major effects on 
brain function in areas of cognition and mood. MRI scanning of the brains of people with 
type 1 diabetes has shown that prefrontal glutamate-glutamine-gamma-aminobutyric acid 
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levels are higher than in healthy control subjects, and these levels correlate with mild 
depressive symptoms [30]. Furthermore, animal models have shown that diabetes negatively 
affects hippocampal integrity and neurogenesis, which may interact with other aspects of 
neuroplasticity and contribute to mood symptoms in diabetes [31]. In humans, hippocampal 
neurogenesis can be indirectly assessed via MRI and there is hippocampal atrophy in 
diabetes [31].
Hypothalamic-Pituitary Adrenal (HPA) Axis Dysfunction
Both depression and diabetes are associated with dysfunction of the hypothalamic-pituitary 
adrenal (HPA) axis, which manifests as subclinical hypercortisolism, blunted diurnal 
cortisol rhythm, or hypocortisolism with impaired glucocorticoid sensitivity, and increased 
inflammation [32].
Sleep
Disrupted sleep patterns are associated with depression [33] and recently, poor sleep quality 
and altered circadian rhythms have been shown to increase insulin resistance and risk of 
type 2 diabetes [34]. In addition, a recent meta-analysis showed that depressive symptoms 
are weakly associated with insulin resistance, providing a potential link to incident type 2 
diabetes [35].
Inflammation
Chronic inflammation may also underlie the association as cytokines and other 
inflammatory markers, such as increased C-reactive protein, TNF-α and proinflammatory 
cytokines, are increased in diabetes and the metabolic syndrome and are implicated in 
causing sickness behavior in animal models and depression in humans [36, 37].
Environmental Factors
These shared biological mechanisms provide a model by which environmental factors, 
ranging from the intra-uterine environment to neighborhood surroundings may affect the 
risk of comorbidity.
There is strong evidence that intrauterine environment and birth weight can predispose 
individuals to type 2 diabetes [38]. The studies of the relationship between adverse intra-
uterine environment and risk for adult depression are less conclusive, but some studies 
suggest a positive association, whereas others have null findings [39–42]. However, in 
human studies, programming of the HPA axis and elevated cortisol reactivity in childhood, 
adolescence, and adulthood, which may predispose the individual to stress-related and 
metabolic disorders, have been seen following both low birth weight and fetal overexposure 
to cortisol secondary to maternal stress [43].
Several environmental factors, including childhood adversity, neighborhood environment 
and poverty influence the predisposition to depression and diabetes. Poor physical (eg, 
physical disorder, traffic, noise, decreased walkability) and social environments (eg, lower 
social cohesion and social capital, increased violence, decreased residential stability) are 
associated with worse diet and lower physical activity patterns, obesity, diabetes, 
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hypertension, and depression [44]. The current studies do not permit a determination of 
causality but adverse neighborhood environments have also been associated with HPA axis 
dysfunction and a blunted circadian rhythm [45–49] as well as enhanced inflammation [50, 
51].
Clinical Consequences of Comorbid Depression and Diabetes
Comorbid depression adversely affects diabetes outcomes and decreases quality of life [52–
54]. A postal survey of 4168 people with diabetes found that, compared with those without 
depression, the 487 people with major depression reported significantly more diabetes 
symptoms and the number of depressive symptoms correlated with the overall number of 
diabetes symptoms [55].
Studies of the relationship between depression and glycemic control in adults have yielded 
discrepant findings with some showing that depression is associated with a small 
deterioration in glycated hemoglobin whereas others have shown no effect [56–58]. In 
children and adolescents, there is a clearer relationship between depressive symptoms and 
poorer glycemic control [15].
Nevertheless, depression is associated with worsened severity across the full range of 
diabetes complications although the direction and mechanisms that underlie this association 
are not fully understood [21].
Depression, even if mild, is also associated with premature mortality through a range of 
physical conditions [59•]. The excess mortality is not wholly explained by an increase in 
known risk factors because in the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) trial, clinically significant depressive scores were an independent risk factor for 
all-cause mortality after adjustment for blood pressure, glycated hemoglobin, lipids, body 
mass index, aspirin use, tobacco, alcohol, living alone, and educational level [60].
Treatment of Diabetes and Depression
Diagnosis of Depression
The first step to the effective management of depression is its recognition and diagnosis. A 
formal diagnosis of depression requires a validated interview but this is time-consuming and 
requires the healthcare professional to consider the diagnosis [61, 62]. Consequently, quick 
and cheaper methods are needed to screen people in primary and secondary care settings 
[63]. Many short questionnaires have been used to screen for depression in the general 
population but only a few have been evaluated adequately in people with diabetes (Table 1) 
[64•]. A number of symptoms, such as lethargy, irritability, or weight change, are common 
to both conditions and so questionnaires that rely heavily on these symptoms may 
overestimate the probability of depression. Table 1 describes the most well validated 
depression screening questionnaires for people with diabetes [64•] and includes the Beck 
Depression Inventory [65], the Centre for Epidemiologic Studies Depression Scale [66], the 
Patient Health Questionnaire (PHQ) [67], and the Hospital Anxiety and Depression Scale 
(HADS) [68]. The most widely used and validated questionnaire in people with type 2 
diabetes is the PHQ-9 [67], which is also the shortest, containing 9 questions and can be 
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completed by the patient. Consequently, it is easy to administer in primary care as well as 
population settings. The cut-off for major depression is ≥10 in primary care populations but 
it has been suggested that increasing the cut-off by 2 points to ≥12 points in people with 
diabetes may improve the discrimination between diabetes related symptoms and depressive 
symptoms [69]. The PHQ-9 has also been extensively used in primary care to assess the 
success of depression interventions using established cut-off scores for remission and 
clinical treatment response.
Another straightforward method that can be used by diabetes healthcare professionals is to 
ask 2 simple questions [70]:
• “During the past month, have you been bothered by having little interest or 
pleasure in doing things?”
• During the past month, have you been bothered by feeling down, depressed, or 
hopeless?”
If the answer to either is “yes,” the patient should be asked if they want help with this 
problem. If the answer to this is also “yes,” then the patient should be formally assessed by a 
diagnostic interview and offered appropriate referral and treatment.
Although a necessary first step, screening alone is insufficient to improve clinical outcomes 
and should be coupled to defined care pathways to allow more intensive depression 
management when required [63]. The importance of linking the screening to on-going care 
was demonstrated in a Dutch randomized controlled trial, which investigated the benefits of 
depression screening. Following screening, written feedback was provided to both patient 
and doctor [71•] but this did not change utilization of mental health services or improve 
depression scores. A further study found that physician recognition and treatment behavior 
was unchanged by screening per se [72].
Treatment
Both psychological therapies and antidepressant medication should be determined on an 
individual basis. As poor metabolic control, low rates of blood glucose self-monitoring, and 
diabetes complications all predict inadequate response to depression treatment, an equal 
emphasis on both diabetes and depression is needed.
Until recently, people with diabetes were specifically excluded from trials of the depression 
treatment and so consequently, there are relatively few studies examining antidepressant and 
psychotherapy treatment of depression in this population. Nevertheless studies published 
over the last decade have clearly indicated that treating depression is effective [73].
Psychological Interventions
The majority of psychotherapy protocols have used cognitive behavioral therapy delivered 
individually by mental health providers [74] or trained nurse case managers [75] but other 
common psychological interventions used in people with diabetes include problem solving, 
interpersonal therapy, motivational interviewing, counselling, and psychodynamic therapy 
[73]. The few published randomized controlled trials have included mixed populations of 
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people with type 1 and type 2 diabetes, despite the fact that these are distinct diseases with 
differing ages of onset that affect the life course differently. The trials have a preponderance 
of people with type 2 diabetes and no trials have been conducted to date with only people 
with type 1 diabetes. There is preliminary evidence to suggest the web-based psychological 
therapies may also be effective in treating depression in people with diabetes but may have 
limited effects on glycemic outcomes [76, 77].
The best response to psychological interventions occurs when these are combined with 
diabetes education, to provide diabetes self-management skills as well as the psychological 
support to use these effectively [73]. As diabetes education often uses psychological 
components, there is the potential to combine the 2 in a seamless way.
Antidepressants
Investigations of antidepressant medications in people with either type 1 or type 2 diabetes 
have shown short-term amelioration of depressive symptoms as long as the medications are 
used in adequate doses, with a response similar to that observed in the general population 
[73]. However, efficacy trials in people with diabetes have been highly heterogeneous in 
terms of study designs (eg, ranging from single case studies to randomized controlled trials) 
and limited to a subset of commonly prescribed antidepressant medications (eg, nortriptyline 
[78], fluoxetine [79–81], bupropion [82], sertraline [83, 84], paroxetine [80], citalopram [81, 
85]). Consequently, there remain substantial gaps in the evidence for effectiveness in 
treating depressive symptoms, effects on glycemic control, and the interaction of side effects 
on diabetes outcomes for other commonly prescribed antidepressants, including venlafaxine, 
desvenlafaxine, milnacipran, levomilnacipran, mirtazapine, nefazodone, and escitalopram 
that have not been investigated. All antidepressants appear to have similar efficacy in terms 
of depression outcomes and so the treatment of choice depends largely on the side effect 
profile, patient preference, and individual response [86]. Selective serotonin re-uptake 
inhibitors are less cardiotoxic than tricyclic antidepressants and are safer in overdose and, 
thus, are the treatment of choice for most people with diabetes. Some antidepressants, 
including mirtazapine, paroxetine and some tricyclic antidepressants, are associated with 
significant weight gain and are less suitable because of worsening insulin resistance and 
potentially glycemic control [87]. By contrast, bupropion, which is available in the USA, is 
associated with weight loss. Furthermore, unlike SSRIs, it does not appear to worsen sexual 
function and, therefore, may have advantages for people with diabetes [88].
There are mixed effects on glycemic control ranging from hyperglycemic effects with 
tricyclic antidepressant medications to euglycemic or slightly hypoglycemic effects with 
selective serotonin reuptake inhibitors and serotonin–nor-adrenaline reuptake inhibitors [73]. 
Sertraline may have specific advantages for glycemic control [73].
Models of Care
At present, many healthcare systems are becoming increasingly fragmented and specialized 
and are ill equipped to manage comorbidity. This disadvantages individuals with comorbid 
physical and mental illness as indicated by the UK Disability Rights Commission, which has 
highlighted the concept of “overshadowing” where healthcare professionals focus solely on 
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the mental disorder and fail to take note of physical health needs, despite the need for this 
care being greater [89]. Within the field of diabetes, this translates into poorer diabetes care; 
those with mental illness are less likely to be screened for diabetes leading to higher rates of 
undiagnosed diabetes [90]. People with comorbid mental illness are less likely to be 
examined for eye or foot complications despite more clinic visits, less likely to be offered 
blood tests to measure glycated hemoglobin or cholesterol, less likely to receive a statin, and 
less likely to receive diabetes education [90]. By contrast, depressive and other mental 
disorders are not sufficiently recognized and treated when they happen to people with 
diabetes or other physical illness [91, 92]. These types of systematic deficiencies within 
healthcare systems may contribute significantly to the poorer health outcomes seen in those 
with comorbid diabetes and depression.
Multidisciplinary team approaches to the identification and treatment of depression within 
primary care settings that incorporate identification of high risk cases, problem-solving 
therapy delivered by trained nurse case managers, and psychotropic medications using a 
stepped-care approach have been shown to deliver the most effective clinical outcomes [75]. 
Early data from the PATHWAYS study indicated positive improvements in depression 
outcomes among adults with type 1 and type 2 diabetes but no changes in glycemic control 
[75]. The subsequent TEAMcare approach combined behavioral and psychotropic 
depression intervention strategies with diabetes management in collaboration with primary 
care and endocrinology teams; the study demonstrated improved depressive symptoms as 
well as glycemic and blood pressure control [93].
Although adults with comorbid diabetes and depression have increased direct and indirect 
health care costs [94•], these models of care appear cost-effective as well as clinically 
effective, leading to fewer days with depression and less out-patient costs [95–97].
Around the world, this level of collaboration is sadly lacking. A recent survey by Diabetes 
UK found that only approximately a third of services had access to specialist psychological 
services [98]. Similarly 81 % of expert providers felt under-resourced to meet patient 
psychological needs because of the demand. More concerning, unlike many other aspects of 
care that have improved in the UK over the last 10 years, the provision of psychological 
support has reduced over the same time [4]. The implication of this is clear; most 
psychological care will be provided by primary care or diabetes teams and extra training and 
awareness are needed to give the health care professionals the necessary skills to achieve 
this. Furthermore, there is an urgent need to improve access to psychological services, not 
least because nonspecialists can provide better care if expert psychological support is 
available. Work is needed to adapt the US collaborative care model to other health services.
Conclusions
Comorbid diabetes and depression is a challenging and under-recognized clinical problem. 
Depressive symptoms affect up to one-third of people with diabetes and not only impair 
quality of life but also add to the difficulties experienced in diabetes self-management. It is 
incumbent on healthcare professionals to identify depression in people with diabetes when 
present and then treat this rapidly and effectively in order to achieve the best clinical 
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outcomes for these individuals. Most health services are poorly equipped to deal with 
comorbidity and, therefore, novel care pathways are needed to address this important public 
health problem.
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Fig. 1. 
Shared biological mechanisms that may underlie both diabetes and depression
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Table 1
Most well validated depression screening questionnaires for people with diabetes
Assessment tool Type of diabetes (n) Type of validation studies in diabetes (n)
Primary Care Health Questionnaire (PHQ-9) [67]
 Self-report measure of depressive symptoms that assessed DSM-IVTR 
diagnostic criteria for Major Depressive Disorder
Type 1 6 Incidence/prevalence 8
Type 2 11 Observational 16
Not reported 16 RCT 1
Beck Depression Inventory (BDI-II) [65]
 21-item self-report measure of depressive symptom severity in the 
prior 2 wk period.
Type 1 25 Incidence/prevalence 11
Type 2 17 Observational 34
Not reported 19 Case–control 4
Experimental 6
Center for Epidemiologic Studies – Depression
 Scale (CESD) [66]
 20-item self-report questionnaire assessing depressive symptom 
severity.
Type 1 10 Incidence/prevalence 17
Type 2 28 Observational 43
Not reported 20 Case–control 4
Validity 3
Hospital Anxiety and Depression Scale (HADS) [68]
 Brief self-report questionnaire assessing symptoms of both anxiety (7 
items) and depression (7 items) during the past wk
Type 1 9 Incidence/prevalence 6
Type 2 11 Observational 20
Not reported 12 RCT 3
Adapted from: Roy T, Lloyd CE, Pouwer F, Holt RI, Sartorius N. Screening tools used for measuring depression among people with Type 1 and 
Type 2 diabetes: a systematic review. Diabetes Med. 2012;29:164–75) [64•].
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